Daewon Pharm. Co., Ltd

Established in 1958, Daewon Pharm specializes in manufacturing prescription drugs, with strong R&D focused on new chemical entities and improved medicines. In 2013, the company recorded $160 million in total sales turnover, exporting ETC and OTC products to more than 30 countries, including emerging markets such as China and Russia, with representative products including Pelubi Tab (pelubiprofen) and Megex-I ES suspension (megestrol acetate).